Oxford University’s Covid-19 vaccine produces good immune response
Clinical trials of the first phase of the coronavirus vaccine led by Oxford University have yielded good results. According to a report published in the medical journal The Lancet on Monday, the vaccine is completely safe and effective. After this information, the Oxford vaccine has come forward in the list of frontrunner vaccines.
In a tweet from Oxford University, it has been said that applying this vaccine has got good immune response. The team involved in the vaccine trial and the Oxford Monitoring Group did not see any safety concerns in the vaccine and the vaccine has led to strong immune response.
Report printed in The Lancet
For this, The Lancet’s Editor-in-Chief Richard Horton has used three special medical terms – safe, well-tolerated and immunogenic. They mean that this vaccine is safe, well tolerated, and produces immunity. Horton has congratulated the vaccine team’s chief scientist, and said that these results are very encouraging.
Two days ago, a July 17 report suggested that this vaccine could offer double protection against coronaviruses. According to the Daily Telegraph, the immune response in volunteers was significantly better after the vaccine was given in the first phase of the trial. Their blood samples were tested. The report revealed that they also contained antibodies against the corona and killer T-cells.
After this, on Sunday, 19 July, Richard was the first to tweet that the results of the Oxford vaccine will be announced on Monday. Horton tweeted, “Tomorrow. Vaccine. Just saying. “This tweet is being discussed everywhere.
Claims to make more antibodies than Corona recovered
AstraZeneca, a pharma company producing vaccines with Oxford University, has claimed in the New England Journal of Medicine that the vaccines given during the trial contained more antibodies than the corona Survivor. Dr. Anthony Fossey, director of the National Institute of Allergy and Infectious Diseases, says the results are good, hoping that the vaccine will succeed.
The trial did not show major side effects
According to Oxford University, serious side effects were not seen during the trial. Only minor problems such as fatigue, headache, chills and body aches occurred. Where there was an injection, there was pain, but this was seen only in cases of overdose.
